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Abstract
Single-domain antibodies (sdAbs) derived from human VH are considered to be less soluble and prone to aggregate which
makes it difficult to determine the crystal structures. In this study, we isolated and characterized two anti-human epidermal
growth factor receptor-2 (HER2) sdAbs, Gr3 and Gr6, from a synthetic human VH phage display library. Size exclusion
chromatography and surface plasmon resonance analyses demonstrated that Gr3 is a monomer, but that Gr6 is a strict
dimer. To understand this different molecular behavior, we solved the crystal structure of Gr6 to 1.6 A ˚ resolution. The crystal
structure revealed that the homodimer assembly of Gr6 closely mimics the VH-VL heterodimer of immunoglobulin variable
domains and the dimerization interface is dominated by hydrophobic interactions.
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Introduction
A typical antibody consists of two heavy-chains (H) and two light-
chains (L) [1]. The N-terminal domains of both H- and L-chains are
variable and are called variable regions [2], abbreviated as VH and
VL. Functionally, the antibodies are consisted of an antigen binding
domain, Fab and an effector domain, Fc. The Fab is composed of
light chain and heavy chain (reviewed by [3]). The antigen binding
sites of conventional antibodies contain six complementary deter-
mining regions (CDRs), three of them from VH and three from VL.
The natural minimal antigen binding domain of such antibodies is
composed of both VH and VL. In camelidae, a significant proportion
of functional antibodies are heavy-chain antibodies which do not
contain light chain [4]. The antigen binding domain of these heavy-
chain antibodies is composed of only VH and is designated as VHH
(reviewed by [5]). This discovery made it possible to isolate soluble
and functional VHH-single domain antibody (sdAbs) [6]. These
sdAbs have many desirable properties from an antibody engineering
point of view. They are relatively small in size with molecular weight
of ,13 kDa and can be engineered to have very high affinities [7].
They can also be amplified and cloned easily because they are
encoded by a single gene. In addition, these sdAbs have favorable
refolding properties and biophysical stability [8]. Furthermore, they
recognize epitopes that are inaccessible to conventional antibodies
[9,10,11]. Finally, sdAb which is injected intravenously into mice
localizes preferentially at the tumor site [12].
Similar types of sdAbs that are derived from human VH [13,14]
are promising in particular for their potential use in immunother-
apy because of their human origin. However, the solubility of these
human sdAbs is one of the main problems. Several approaches
have been reported to obtain soluble VH sdAbs [13,15],
nevertheless structural information of such sdAbs is limited. The
absence of light chain leads to exposure of the hydrophobic VH-VL
interacting interface which can cause aggregation [16]. Hence, the
structural information of such human VH sdAbs is very limited. In
this regard, we used a synthetic human VH library [17] to isolate a
panel of soluble sdAbs against human epidermal growth factor
receptor-2 (HER2). The isolated sdAbs have affinities in the
nanomolar range. We chose two sdAbs, Gr3 and Gr6, for further
evaluation. The difference of the amino acid sequences between
these sdAbs is restricted to their CDR1 and CDR3. Expression
levels of both sdAbs as soluble protein were comparable. Size
exclusion chromatography (SEC) analysis demonstrated that Gr3
exists as a monomer, whereas Gr6 is a dimer. To our knowledge,
Gr6 is the first human-derived sdAb that is a strict homodimer.
Therefore, we determined the crystal structure of Gr6 which
showed that the structure mimics the VH-VL pairing.
Results
Selection of HER2-specific sdAbs
A human VH phage display library [15,17] was used to select
HER2-binding sdAbs as described [18] with the exception that the
first two rounds of panning were performed on MDA-MB-231-
Erb2 cells and the third and fourth round on the HER2/Fc
protein. Ninety six randomly picked clones were tested on phage
ELISA to identify clones displaying HER2-specific VH, of which
25 scored positive. DNA sequencing of the 25 clones revealed 7
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e30149different VHs, namely Gr1, Gr2, Gr3, Gr4, Gr5, Gr6 and Gr7.
Gr1 was represented by 12 clones, Gr2 by 4 clones, Gr3 by 3
clones, Gr4 and Gr5 by 2 clones, and Gr6 and Gr7 by 1 clone.
Characterization of the sdAbs Gr3 and Gr6
The seven different VHs were sub-cloned in the expression
vector pSJF2H [17]. After sequence verification, the sdAbs were
expressed as 6xHIS-tagged soluble protein in the periplasm and
purified by IMAC using a Ni-NTA column. This one-step
purification resulted in more than 95% pure protein when
assessed with SDS-PAGE (data not shown). The expression of
Gr1, Gr2, Gr4, Gr5 and Gr7 was low and therefore were not used
further. Like most of the soluble human sdAbs, Gr3 exists as a
pure monomer seen as a single peak eluted at a volume
corresponding to the apparent molecular mass of , 15 kDa in a
SEC analysis using a Superdex
TM 75 column (Fig. 1A). However,
Figure 1. Characterization of Gr3 and Gr6 in solution. (A) Size exclusion chromatography of IMAC-purified Gr3 and Gr6 using a Superdex
TM 75
column. (B) Amino acid sequences of Gr3 and Gr6 numbered according Kabat numbering [19]. (C) Binding of Gr3 and Gr6 to HER2/Fc analyzed by
SPR.
doi:10.1371/journal.pone.0030149.g001
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molecular mass of , 30 kDa. This result demonstrated that Gr6
exists as a dimer in solution. Because of this difference, we chose
Gr3 and Gr6, which differ only in CDR1 and CDR3 in their
amino acid sequences (Fig. 1B.) for further characterization.
The affinity of these sdAbs to HER2 was determined with
surface plasmon resonance (SPR). Injection of sdAbs at concen-
tration of 5 to 600 nM onto HER2-coupled surface revealed
specific binding of the sdAb to the antigen. For Gr3, the actual
association and dissociation curves fitted excellently to the 1:1
Langmuir binding model, giving an association rate constant (ka)o f
2.9610
5 M
21s
21, a dissociation rate constant (kd) of 2.0610
22 s
21
and a dissociation equilibrium constant (KD) of 6.8610
28 M
(Fig. 1C). For Gr6, the ka, kd and KD were 4.5610
5 M
21s
21,
1.0610
21 s
21 and 2.2610
27 M, respectively (Fig. 1C).
Circular dichroism (CD) profiles of Gr3 and Gr6 were
determined to estimate the thermostability of the sdAbs.
Thermo-induced denaturation of the protein was measured in
the temperature range of 25 to 91 uC with 2 uC intervals. Plotting
the CD value at 217 nm against temperature suggested a two
phase denaturation (Fig. 2) with a calculated melting temperature
(Tm)o f6 6uC for Gr3 and 79 uC for Gr6, respectively.
Crystal structure of Gr6
Gr6 is a dimeric protein of 140-amino-acid residues and the
crystal structure has been solved to 1.6 A ˚ resolution by molecular
replacement method (Fig. 3A). The majority of the electron
density is well-defined which allows for unambiguously model
building. The first three residues at the N-terminus in monomer A
and the first four residues in monomer B are disordered in the
map. In addition, the C-terminus of the last 12 residues in
monomer A and 13 residues in monomer B, as well as the 6xHIS
tag, could not be traced in the map. Kabat nomenclature [19] is
used to number the positions of the amino acids and for the
description of the structure. The crystallographic analysis showed
that two molecules are present in the asymmetric unit in which
one molecule is related to the other by a non-crystallographic 2-
fold axis to form a dimer. The refined model includes residues
Val2-Gly114 in monomer A and residues Gln3-Ser113 in
monomer B as well as 266 water molecules. The residues for b -
strand assignments are: 3-12 (strand A), 17-25 (strand B), 32-40
(strand C), 44-52 (strand C’), 56-60 (strand C’’), 66-73 (strand D),
76-82b (strand E), 87-96 (strand F), and 102-112 (strand G).
Validation of the structure by program SFCHECK [20] showed
that the refined model is of good stereochemical quality (Table 1)
and that no phi-psi angles are in the disallowed regions of the
Ramachandran map.
The monomer structure of Gr6 has the same fold as the
canonical immunoglobulin variable domain, consisting of two b -
sheets with five and four strands. Gr6 shares 76% sequence
identity with the camelized human antibody fragment cVH-E2, an
inhibitor of the NS3 serine protease of hepatitis C virus [21] (PDB
code 1OL0), and 62% identity with the VH domain of the human
Fv-POT [22] (PDB code 1IGM). Superimposition (Fig. 3B) of the
monomer structure of Gr6 to the monomer structure of cVH-E2
and to the VH domain of human Fv-POT yields the root mean
square deviation of 0.60 A ˚ and 0.58 A ˚ (117 and 102 Ca atoms,
respectively). The conformations of the hypervariable loops CDR1
(residues 26-35) and CDR2 (residues 51-64) of Gr6 are similar to
those of cVH-E2 and Fv-POT. The CDR3 loop (residues 95-102)
of Gr6 exhibits a very different structure from the CDR3 loops of
cVH-E2 and Fv-POT. A unique feature of the Gr6 structure is that
CDR3 protrudes beyond the boundary of dimer interface and
points to the other side of the other monomer.
Analysis of the dimer interface and the accessible surface area
(ASA) was computed by PISA in CCP4 program package [23] and
through the Protein Interactions Calculator website (http://crick.
mbu.iisc.ernet.in/ ˜PIC) [24]. The total buried ASA at the interfaceof
approximately 2200 A ˚ 2 is contributed from both monomers of ,
1100 A ˚ 2. The interactions between monomers are predominantly by
hydrophobic contacts involving residues Val37, Leu45, Trp47,
Ala50, Tyr58, Tyr91, Val93, Leu95, Pro96, Leu98, Ala101 and
Trp103. Polar interaction in the interface includes 9 direct hydrogen
bonds.Nosaltbridgesandwatermoleculesarefoundthroughoutthe
interface. The arrangement of the Gr6 homodimer resembles the
structure of Fv-POT. Superimposition structure of Gr6 with
structure of Fv-POT [22] (PDB code 1IGM) reveals that two VH
domains in Gr6 structure maintain the same relative orientation
between VH and VL in the structure of Fv-POT (Fig. 3C).
Discussion
Single-domain antibodies are very attractive tumor-targeting
tools for their natural properties of small size, solubility and high
Figure 2. Melting temperature (Tm) measurements of Gr3 and
Gr6 by CD spectroscopy. Melting temperature (Tm) measurements
of Gr3 and Gr6 by CD spectroscopy. The CD values measured at 217 nm
are plotted against temperature ranging from 25uCt o9 1 uC. The solid
line shows the fitted values using GraphPad Prism software (GraphPad
Software Inc., La Jolla, CA).
doi:10.1371/journal.pone.0030149.g002
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PLoS ONE | www.plosone.org 3 January 2012 | Volume 7 | Issue 1 | e30149Figure 3. Structure of Gr6 and comparison of Gr6 with cVH-E2 and Fv-POT. (A)R i b b o nd i a g r a mo ft h eG r 6s t r u c t u r es h o w ni nc y a n( c h a i nA )a n d
red (chain B). CDRs are colored in green in chain A and orange in chain B. The b-strands are labeled by following the Kabat nomenclature. (B) Ribbon
diagram ofthe superimposed Fv-POTHeavychainontothemonomerofGr6(left)andthesuperimposedcVH-E2monomerontoGr6monomer(right):cyan,
Gr6; light pink, Fv-POT heavy chain; light blue, cVH-E2. (C) Ribbon diagram of the superimposed Fv-POT and Gr6 dimer: light pink, Fv-POT; cyan, Gr6.
doi:10.1371/journal.pone.0030149.g003
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their high thermodynamic stability [8]. This feature not only
contributes to the high expression yield, but may also be required
for their in vivo tumor targeting ability [25]. In this study, we
isolated and characterized two anti-HER2 sdAbs, Gr3 and Gr6,
from a semi-synthetic human VH library. The Tms calculated from
CD experiments for both Gr3 and Gr6 are in the same range as of
that of the camelid sdAb. Therefore, we presume that these
human sdAb are as stable as camelid sdAb. The single domain
antibodies are also known for their monomeric behavior. In
solution, Gr3 exists as a monomer; however, Gr6 has an unusual
nature of being a strict dimer. To our knowledge, Gr6 is the first
sdAb derived from human VH with this characteristics and the
solved crystal structure of Gr6 presented here is the first structure
of human sdAb with a dimeric conformation.
The crystallographic data presented here shows that Gr6 exists
as a homodimer, consistent with the SEC analysis result. The
framework structure of Gr6 is identical to other immunoglobulin
variable domains, composed of nine b-strands forming two b-
sheets. The dimer interface of Gr6 structure is contributed by
hydrophobic interaction formed by residues located on b-strands F
and G, part of the CDR3 loop and b -strands C and C’’ (Fig. 4A
and 4B). Among those residues, Val37, Leu45, Trp47, Ala50,
Trp103 are the hall mark residues situated at the VH-VL
heterodimer interface of the immunologlobulin variable domain
[19,26,27]. Superposition of these hallmark residues of Gr6 with
that of Fv-POT shows structural resemblances (Fig. 4C) that
suggest the Gr6 dimer association mimics VH-VL interaction.
Interestingly, among all residues contributing to Gr6 dimer
formation, eight of them, Val37, leu45, Trp47, Ala50, Tyr58,
Tyr91, Val93 and Trp103, are identical between Gr3 and Gr6.
The first three amino acids, Val37, Leu45 and Trp47 are
substituted to Phe37, Arg45 and Gly47 in camelid VHH and are
considered to be hallmark substitutions that make these sdAbs
more soluble [28,29]. However, Gr3 which contains all of these
three hydrophobic residues is monomeric and soluble.
The other four residues that contribute to the Gr6 dimerization,
Leu95, Pro96, Leu98 and Ala101 positioned on CDR3 loop are
unique to Gr6. This suggests that these residues play essential roles
in Gr6 dimer formation and replacement of these residues in Gr3
(Leu95-Pro, Pro96-Glu, Leu98-Gln, Ala101-Arg) disrupts the
inter-domain interaction. It is interesting to note here a change
in the character of CDR3 in Gr3 and Gr6. It is hydrophobic in
Gr6 but polar/charged in Gr3, thus promoting the change from a
dimer to a monomer. This result provides at least an exception of
the suggestion that solubility and stability of VH is independent of
the CDR3 sequence [16].
The observed relatively large buried ASA , 2200 A ˚ 2 suggests
that the Gr6 structure is a compact dimer. The camelized human
antibody fragment cVH-E2, a competitive and reversible inhibitor
of the NS3 protease of the hepatitis C virus, is a concentration-
dependent dimer which occurs in solution at protein concentration
. 7m gm L
21 [21]. The dimerization of cVH-E2 should be the
consequence of the selected CDR3 loop because the molecule was
affinity-selected from a library in which CDR3 is randomized,
implying that CDR3 should be involved in the dimerization [21].
However, in the crystal structure of cVH-E2 dimer, the CDR3
loops are at the opposite sides of the molecule and do not
participate in the inter-domain interaction [21]. Therefore, the
crystallographic structure of cVH-E2 is probably a result of crystal
packing and may not represent the observed dimer in solution. In
this work, the Gr6 crystal structure shows that the VH-VH
interface mimics the classical association of VH-VL dimer, strongly
suggesting that Gr6 is a strict dimer and that the structure does
represent the dimerization in solution.
The Gr6 structure present here not only provides information
on how the dimer is associated, but also confirms that the
dimerization of the sdAb cannot avoid the traditional VL-binding
interface. More studies are required to understand whether Gr3/
Gr6 can block the dimerization of HER2, whether Gr3/Gr6 can
specifically target high HER2 expression cells, and how Gr3/Gr6
interacts with HER2. Although trastuzumab (Herceptin, Genen-
tech Inc., San Francisco, CA) is an approved therapy for treating
HER-2 dependent cancers, the development of trastuzumab
resistance occurred within one year after the patients received
the initial response to trastuzumab [30]. One of the problems with
trastuzumab is that it does not efficiently block HER2 from
dimerizing with other HER family members. Therefore, Gr3 and
Gr6 could be alternative HER2-targeted antibodies that possess
the advantage of accessibility to hidden antigens that are not easily
reached by whole antibodies. The characterization and structural
information obtained in this work therefore will be beneficial to
the future design of such humanized sdAbs in the HER2-
dependent cancer therapy.
Materials and Methods
Selection of binders
The synthetic phagemid-based human VH library used in this
study has been previously described [15,17]. VH repertoire was
Table 1. Crystallographic data and refinement statistics.
Data collection
Space group P212121
Cell dimensions
a, b, c (A ˚) 39.81, 76.99, 81.36
a, b, c (u) 90.0, 90.0, 90.0
Wavelength 1.000
Resolution (A ˚) 20.0 – 1.6 (1.66 – 1.60)
Rmerge
a 0.052 (0.525)
I/sI 42.5 (3.0)
Completeness (%) 99.4 (99.0)
Redundancy 6.4 (6.3)
Refinement
No. reflections 32282
Rwork
b/Rfree
c 20.91/22.89
No. atoms
Protein 1832
Water 266
B-factors
Protein 25.43
R.m.s. deviations
Bond lengths (A ˚) 0.0047
Bond angles (u) 1.37
The values in parenthesis are for the highest resolution bin.
aRmerge = Rwork = ShSi|Ihi - ,Ih.|/ShSiIhi, were Ihi is the ith observation of the
reflection h, while ,Ih. is the mean intensity of reflection h.
bRfactor = S||Fo|-| F c||/|Fo|. Rfree was calculated with a small fraction (6.7%) of
randomly selected reflections.
cThe Rfree was calculated from 6.7% of all data that were not used in the
refinement.
doi:10.1371/journal.pone.0030149.t001
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PLoS ONE | www.plosone.org 5 January 2012 | Volume 7 | Issue 1 | e30149Figure 4. Hydrophobic interface of Gr6 dimer. (A) View of side chain arrangement at the VH-VH hydrophobic interface of Gr6 homodimer. One
Gr6 monomer is shown in cyan and the other one is shown in gray. (B) Surface representation of VH. Residues involved in dimer formation are
highlighted in yellow. (C) Superposition of residues at VH-VH interface of Gr6 with that at VH-VL interface of Fv-POT to show the structural
resemblances of the residues that are located at framework-2 involved in the dimer formation.
doi:10.1371/journal.pone.0030149.g004
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described [18]. Specific VHs against HER2 were enriched by four
rounds of in vitro selection. In the first two rounds MDA-MB-231-
ErbB2 cells, a kind gift from Dr. Maria Jaramillo, NRC Canada,
were used as the antigen. Three wells each with 1.5 million cells
were incubated with 5610
12 phages displaying VH. For the 3
rd
and 4
th round of panning human HER2 (ErbB2)/Fc chimera
(R&D Systems Inc, Minneapolis, MN) at the concentration of
100 mgm L
21 was used. 100 mM triethylamine at pH 11.0 was
used to elute bound phage which were immediately neutralized
with 1 M Tris-HCl at pH 7.4 and were used to infect
exponentially growing TG1 cells.
Individual colonies obtained after fourth round of panning were
tested against HER2 in a phage ELISA according to the standard
procedures. Briefly, clones were grown in 2 6 YT medium +
ampicillin (100 mg mL
21) 0.1% glucose to OD600 = 0.3–0.5, and
infected with M13K07 helper phage (37uC no shaking, 30 min)
followed by addition of kanamycin (50 mgm L
21) and incubation
overnight (37uC with shaking). Cultures were centrifuged
(4000 rpm, 20 min, 4uC) to pellet the cells. Subsequently 100 mL
of supernatant containing recombinant phage particles were
added to HER2 (ErbB2)/Fc chimera pre-coated microtiter plate
wells. After a 2 h incubation at 37uC, microtiter plate wells were
washed three times with PBS plus 0.1% (v/v) Tween 20 followed
by addition of 1:5000 diluted anti-M13 HRP conjugate (GE
Healthcare, Baie d’Urfe ´, QC). VH-phages bound to HER2 were
detected by the addition of 100 mL of HRP substrate. After a
15 min incubation the reaction was stopped by adding 100 mLo f
1MH 3PO4 and absorption at 405 nm was measured.
Expression and purification of sdAbs
The VH genes of the clones that scored positive in phage ELISA
were sequenced to examine the diversity of the isolated clones.
They were re-cloned into the expression vector pSJF2H
30 using
the restriction enzymes BbsI and BamHI. The ligated plasmids
were used to transform E. coli cells. After sequence re-
confirmation, recombinant sdAbs proteins were expressed in the
periplasm and purified by immobilized-metal affinity chromatog-
raphy (IMAC). Briefly, clones were inoculated overnight in 25 mL
LB with 100 mgm L
21 ampicillin at 37uC and 200 rpm. Twenty
milliliter of the culture was transferred to 1 L of M9 medium (0.2%
glucose, 0.6% Na2HPO4, 0.3% KH2PO4, 0.1% NH4Cl, 0.05%
NaCl, 1 mM MgCl2, 0.1 mM CaCl2) supplemented with 0.4%
casamino acids, 5 mgm L
21 vitamin B1 and 100 mgm L
21
ampicillin and incubated for 24 h. Hundred milliliter of 10 6
TB nutrients (12% Tryptone, 24% yeast extract and 4% glycerol),
2 mL of 100 mgm L
21 ampicillin and 1 mL of 1 M isopropyl-b-D-
thiogalactopyranoside (IPTG) were added to the culture and
incubation was continued for another 65 - 70 h at 28uC and
200 rpm. Cells were then centrifuged and the pellets were lysed
with lysozyme. Cell lysates were centrifuged and supernatants
were loaded onto 5-mL HiTrap
TM chelating HP affinity columns
(GE Healthcare). After washing the columns with four column
volume of wash solution (10 mM HEPES buffer, 500 mM NaCl,
20 mM imidazol, pH 7.5), His-tagged proteins were eluted with a
linear gradient (10 to 500 mM) of imidazole and the eluted
proteins were assessed for purity by SDS-PAGE and subsequently
dialyzed in PBS buffer. The aggregation status of sdAbs was
assessed by Superdex
TM 75 size exclusion chromatography (SEC)
as described using PBS as the equilibration buffer [31].
Thermostability determination of sdAbs
To determine the circular dichroism (CD) profile and
thermostability of the sdAbs, proteins were first buffer-exchanged
in 10 mM phosphate buffer, pH 7.0, by a Superdex
TM 75 SEC.
The peaks for the sdAbs were collected, and the proteins were used
for CD analysis. CD spectra were collected from 250 to 200 nm at
protein concentrations of 2.5 mM in a 10 mm quartz cuvette with
a J-850 CD spectropolarimeter (JASCO, Easton, MD). Data were
collected with a band width of 1.0 nm and a scanning speed of
50 nm min
21 with two accumulations of scans to determine the
CD profile of the proteins. Under the same conditions but with a
single data accumulation, CD spectra were automatically
measured at 2uC intervals from 25–91uC to determine thermal
denaturation of the protein at a temperature shift speed of 1uC/
min. Ellipicity at 217 nm were plotted against temperature and
melting temperatures (Tms) were calculated from Boltzmann
Sigmoidal equation using GraphPadPrism software.
Affinity measurement of sdAb by surface plasmon
resonance (SPR)
The binding of sdAbs to HER2 was determined by SPR using a
Biacore 3000 (GE Healthcare). HER2 and ovalbumin (as
reference protein, Sigma) were immobilized on research grade
sensor chip CM5 (GE Healthcare). Immobilizations were
performed with an amine-coupling kit (GE Healthcare) and
carried out at 50 mgm L
21 HER2 in 10 mM acetate, pH 4.0 (GE
Healthcare) and 50 mgm L
21 of ovalbumin in 10 mM acetate,
pH 4.5. A volume of 120 mL of the sdAb at concentration of 5 nM
to 600 nM were injected over the surfaces at a flow rate of 40 mL/
min. Analyses were carried out at room temperature in HBS-EP
(10 mM HEPES pH 7.4, 150 mM NaCl, 3 mM EDTA and
0.005% surfactant P20 (GE Healthcare). Regeneration was
performed with running buffer (HBS-EP). Data were analyzed
with BIAevaluation software 4.1 (GE Healthcare).
Crystallization and data collection
Various commercial kits of Hampton Research and Emeralds
BioSystems were used for initial screening of crystallization
conditions for Gr6 protein, by vapor diffusion method performed
with a Honeybee 961 robot (Digilab Genomic Solutions). Gr6
crystals were obtained in sitting drops mixing 0.5 mL of protein
(30 mg mL
21 in 10 mM HEPES pH 7.0, 100 mM NaCl) with
0.5 mL of precipitant solution (100 mM Bicine buffer, pH 9.0,
20% (w/v) PEG 6000). Temperature was an important factor for
the growth of Gr6 crystals. The plate-shaped crystals grew in the
way that crystallization trays were incubated at 25uC for 2 days,
and then shifted to 4uC. Crystals grew to maximum dimension ,
0.3060.5060.03 mm within 2 weeks. Crystals in the mother
liquor were flash-frozen in liquid nitrogen prior to data collection.
The native data set was collected to 1.6 A ˚ resolution with the
wavelength l=1.0 A ˚ at beamline 13B1 of the National Synchro-
tron Radiation Research Center, Hsinchu, Taiwan. Crystals were
kept at 100 K during data collection. Data were indexed,
integrated and scaled with HKL2000 [32]. The space group is
P212121 with the unit cell dimensions a=39.81 A ˚, b=76.99 A ˚
and c=81.36 A ˚. The Matthew’s coefficient is 2.34 A ˚ 3/Da with
two molecules per asymmetric unit corresponding to solvent
content of 47.4%. Crystal parameters and data collection statistics
are summarized in Table 1.
Structure determination and refinement
The Gr6 structure was solved by molecular replacement with
the program Phaser [33], using data between 20 and 2.5 A ˚. The
monomer structure of the camelized human antibody fragment
cVH-E2 (PDB code 1OL0) [21] was used as the search model and
two copies of the molecule were applied in the search. The best
Structure of a Dimeric Human sdAb
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model was rebuilt with the program Coot [34] with the guidance
of the 2Fo-Fc and Fo-Fc electron density maps. Refinement of the
model was carried out with the program CNS [35] without any
non-crystallographic symmetry restraints. Multiple cycles of
simulated annealing, positional, and individual isotropic B factor
refinements against data to 1.6 A ˚ resolution were performed with
CNS, alternating with manual model rebuilding in Coot. 6.7% of
the data were flagged for cross-validation during refinement. Total
of 266 water molecules were included in the final model and final
stage of the refinement. The refinement statistics are summarized
in Table 1.
PDB accession code
Coordinates and structure factors have been deposited in the
Protein Data Bank with the identifier 3QYC.
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